20 December 2012
Evolva successfully discussed clinical development plans for EV-077 in diabetes patients with German regulatory authority
29 November 2012
Evolva acquires resveratrol programme from Fluxome
21 November 2012
Evolva selected to acquire certain Fluxome Sciences assets
26 September 2012
Evolva reaches first milestone in Roquette collaboration
10 September 2012
Evolva's antibiotic EV-035 selected for an oral presentation at key scientific congress ICAAC
30 August 2012
Evolva reports interim results for first six months of 2012
17 August 2012
Evolva's EV-077 achieved objectives in first group of patients in Phase IIa trial
21 June 2012
Evolva reaches first milestone in IFF collaboration
03 May 2012
Evolva expands collaboration with IFF
22 March 2012
Evolva reports financial results 2011, a year where emphasis shifted to nutrition and consumer products
05 March 2012
Evolva presents promising novel antibiotic at Superbugs and Superdrugs Conference
29 February 2012
Swiss-based Evolva Holding SA successfully completes its US biodefense program
02 January 2012
Evolva collaborates with Roquette, a world leader in the area of nutrition
Evolva successfully discussed clinical development plans for EV-077 in diabetes patients with German regulatory authority
29 November 2012
Evolva acquires resveratrol programme from Fluxome
21 November 2012
Evolva selected to acquire certain Fluxome Sciences assets
26 September 2012
Evolva reaches first milestone in Roquette collaboration
10 September 2012
Evolva's antibiotic EV-035 selected for an oral presentation at key scientific congress ICAAC
30 August 2012
Evolva reports interim results for first six months of 2012
17 August 2012
Evolva's EV-077 achieved objectives in first group of patients in Phase IIa trial
21 June 2012
Evolva reaches first milestone in IFF collaboration
03 May 2012
Evolva expands collaboration with IFF
22 March 2012
Evolva reports financial results 2011, a year where emphasis shifted to nutrition and consumer products
05 March 2012
Evolva presents promising novel antibiotic at Superbugs and Superdrugs Conference
29 February 2012
Swiss-based Evolva Holding SA successfully completes its US biodefense program
02 January 2012
Evolva collaborates with Roquette, a world leader in the area of nutrition
